

FORM PTO-1390 (Modified)
(REV 10-95)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371

193665US0PCT

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR

09/581549

INTERNATIONAL APPLICATION NO.
PCT/JP99/00083INTERNATIONAL FILING DATE
13 JANUARY 1999PRIORITY DATE CLAIMED
14 JANUARY 1998TITLE OF INVENTION
DISINTEGRANTAPPLICANT(S) FOR DO/EO/US
Toshio MURAKAMI, et al.

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371 (c) (2))
 - a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☒ has been transmitted by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☒ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☒ A copy of the International Search Report (PCT/ISA/210).
8. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☒ have not been made and will not be made.
9. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
10. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).
11. ☐ A copy of the International Preliminary Examination Report (PCT/IPEA/409).
12. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).

Items 13 to 18 below concern document(s) or information included:

13. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
15. ☐ A **FIRST** preliminary amendment.
A **SECOND** or **SUBSEQUENT** preliminary amendment.
16. ☐ A substitute specification.
17. ☐ A change of power of attorney and/or address letter.
18. ☐ Certificate of Mailing by Express Mail
19. ☒ Other items or information:

Request for Consideration of Documents Cited in International Search Report

Notice of Priority

PCT/IB/304

PCT/IB/308

Drawings (3 Sheets)

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR 1.53) 09/581549		INTERNATIONAL APPLICATION NO. PCT/JP99/00083		ATTORNEY'S DOCKET NUMBER 193665US0PCT	
--	--	--	--	---	--

20. The following fees are submitted:

BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) :

<input checked="" type="checkbox"/> Search Report has been prepared by the EPO or JPO	\$840.00
<input type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482)	\$670.00
<input type="checkbox"/> No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2))	\$760.00
<input type="checkbox"/> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO	\$970.00
<input type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4)	\$96.00

ENTER APPROPRIATE BASIC FEE AMOUNT =

Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492 (e)).	\$0.00
---	---------------

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	
Total claims	6 - 20 =	0	x \$18.00	\$0.00
Independent claims	4 - 3 =	1	x \$78.00	\$78.00
Multiple Dependent Claims (check if applicable). <input checked="" type="checkbox"/>				\$260.00
TOTAL OF ABOVE CALCULATIONS =				\$1,178.00
Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28) (check if applicable). <input type="checkbox"/>				\$0.00
SUBTOTAL =				\$1,178.00
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492 (f)).				\$0.00
TOTAL NATIONAL FEE =				\$1,178.00
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable). <input type="checkbox"/>				\$0.00
TOTAL FEES ENCLOSED =				\$1,178.00

	Amount to be: refunded	\$
	charged	\$

CALCULATIONS PTO USE ONLY

☒ A check in the amount of **\$1,178.00** to cover the above fees is enclosed.

☐ Please charge my Deposit Account No. _____ in the amount of _____ to cover the above fees.
A duplicate copy of this sheet is enclosed.

☒ The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Deposit Account No. **15-0030** A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C.
 1755 Jefferson Davis Highway, Fourth Floor
 Crystal Square Five
 Arlington, Virginia 22202
 703-413-3000

Surinder Sachar
Registration No. 34,423

Norman F. Oblon

SIGNATURE

Norman F. Oblon

NAME

24,618

REGISTRATION NUMBER

July 13, 2000

DATE

534 Rec'd PCT/PTC 13 JUL 2000

Description

Disintegrant

Technical Field

The present invention relates to a disintegrant which is incorporated into solid compositions used in the fields of drug products, health food products, etc.

Background Art

Orally administered drugs or health foods exhibit their effects after they reach the digestive organs, at which point pharmaceutically active ingredients or nutritional ingredients contained therein are absorbed through the organs and then distributed within the body. Examples of product forms for oral administration include tablets, capsules, granules, fine granules, pills, and powders. Many modifications have been made to these product forms in order to enhance absorbability of pharmaceutically active ingredients or nutritional ingredients in the body and to improve sensation upon taking of the products.

When a pharmaceutical composition has poor disintegrability, elution of pharmaceutically active ingredients therefrom within the digestive organs is unsatisfactory, reducing the absorbability of the ingredients. In order to enhance disintegrability of such a composition, a water-swellable disintegrant is incorporated into the

composition. Examples of widely-used water-swellable disintegrants include low substituted degree hydroxypropyl-cellulose, crosscarmellose sodium, carmellose, and carmellose calcium.

Such a water-swellable disintegrant is water-insoluble, but the volume thereof increases when the agent absorbs moisture or comes into contact with water. Therefore, in order to incorporate the agent into a solid composition such as a tablet, the composition must be designed in consideration of reduction in hardness of a tablet or increase in volume of the composition due to moisture absorption. Particularly, in the case of film-coated tablets and sugar-coated tablets, if a water-swellable disintegrant is incorporated into the composition before coating, the tablets may absorb moisture with passage of time, resulting in cracking or breakage of a film-coated layer or sugar-coated layer. Incidentally, cellulose is a fibrous substance having a relatively large particle size. Therefore, a composition containing cellulose is disadvantageous, in that it is apt to provide a gritty sensation in the oral cavity upon administration, causing an unfavorable sensation upon oral administration. Particularly, cellulose exhibits such adverse effects on powders, granules, or shaped products which rapidly disintegrate or dissolve in the oral cavity.

In order to improve disintegrability of a solid composition, the aforementioned water-swellable disintegrant is generally incorporated therein. Another known method to

Brief Description of the Drawings

Fig. 1 is a graph showing the relation between disintegration time (i.e., time required for disintegration) and hardness in Examples 1-1 through 1-3 and Comparative Example 1. Fig. 2 is a graph showing the relation between disintegration time and hardness in Example 2 and Comparative Examples 2-1 and 2-2. Fig. 3 is a graph showing the relation between disintegration time and hardness in Example 3 and Comparative Examples 3-1 and 3-2.

Best Mode for Carrying Out the Invention

The term "the disintegrant of the present invention" refers to a disintegrant comprising a substance which is solid at room temperature and has a water solubility of 30 wt.% or more at 37°C, a saturated aqueous solution of the substance having a viscosity of 50 mPa·s or less at 37°C. As used herein, the term "room temperature" refers to a temperature of 1-30°C. The disintegrant of the present invention is preferably solid at 30°C.

When the disintegrant of the present invention is incorporated into a solid composition, permeability of water into the composition is enhanced, since the disintegrant of the present invention has high water solubility and high rate of dissolution into water, and a saturated aqueous solution of the agent has low viscosity. The solid composition is considered to disintegrate and dissolve with dissolution of the disintegrant. In addition, the solid composition is

hydrate are 155°C or higher and 120-130°C, respectively. Maltose is easily dissolved in water and is a sweetener having a sweetness of approximately 33% that of sucrose.

The disintegrant of the present invention is appropriately incorporated into a solid composition in an amount of 5-99 wt.% on the basis of the entirety of the composition, preferably 10-99 wt.%, more preferably 20-99 wt.%. When the amount is less than 5 wt.%, the effect of the agent for ameliorating disintegration or dissolution of the composition is insufficient, resulting in poor disintegrability and solubility of the composition.

Erythritol, trehalose, xylitol, and maltose can be employed as an excipient, and thus even when they are incorporated into a solid composition in large amounts, no problem arises in the composition. The greater the amount of these agents contained in a solid composition, the more enhanced the effect of the agents for ameliorating disintegration or dissolution of the composition. However, when erythritol is incorporated into a tablet, the amount of erythritol is appropriately 80 wt.% or less, because when erythritol is incorporated into a tablet in large amounts, shapability of the tablet may deteriorate, which causes the tablet to have low hardness.

The disintegrant of the present invention exhibits effects for ameliorating disintegrability or solubility of a solid composition. Particularly, the agent is suitably employed for ameliorating disintegrability of a crude film-

coated tablet or sugar-coated tablet. For example, erythritol has no hygroscopicity or swellability, and thus even when erythritol is incorporated into a crude film-coated or sugar-coated tablet in large amounts, the tablet does not undergo cracking or breakage due to moisture absorption with passage of time. When erythritol is incorporated into a solid composition together with a conventionally-employed water-swellaable disintegrant such as low substituted hydroxypropylcellulose, the amount of such a conventional water-swellaable disintegrant can be reduced. Therefore, the size of the composition can be reduced.

The disintegrant of the present invention is effectively incorporated into powders, granules, chewable tablets, or shaped products which rapidly disintegrate or dissolve in the oral cavity. Namely, the disintegrant of the present invention, which differs from conventionally-employed cellulose such as low substituted hydroxypropylcellulose, is not a fibrous substance, and thus a solid composition containing the agent does not provide a gritty sensation in the oral cavity. In addition, the composition dissolves rapidly in the oral cavity, and the composition can provide a favorable sensation on oral administration.

In the present invention, the product shape of a solid composition is not particularly limited. Examples of the product shape include tablet, troche, capsule, granule, powder, and pill. Examples of tablets include chewable tablets, effervescent tablets, and shaped products which

dissolve and disintegrate in the oral cavity and which can be administered orally without aid of water. Examples of granules and powders include dry syrups which are dissolved upon use and granular products which dissolve and disintegrate in the oral cavity and can be administered orally without aid of water.

The disintegrant of the present invention may be incorporated into drug products and health food products. No particular limitation is imposed on the species of pharmaceutically active ingredients or nutritional ingredients contained in drugs and health foods according to purposes. These ingredients may take any form, such as powder, crystal, oil, or solution.

Examples of ingredients contained in drug products and health food products include vitamin A, vitamin B₁ (e.g., thiamin hydrochloride), vitamin B₂, vitamin B₆, vitamin B₁₂, vitamin C (e.g., ascorbic acid, sodium ascorbate), vitamin D, vitamin E, nicotinamide, calcium pantothenate, pantethine, epsilon aminocaproic acid, tranexamic acid, gamma aminobutyric acid, carpronium chloride, procainamide hydrochloride, alimemazine tartrate, isoniazid, pilsicainide hydrochloride, ticlopidine hydrochloride, cinepazide maleate, sulpyrine, aspirin, acetaminophen, ethenzamide, ibuprofen, ketoprofen, indomethacin, cimetidine, famotidine, caffeine, ofloxacin, levofloxacin, nalidixic acid, carvedilol, sulfadimethoxine, reserpine, lofepramine hydrochloride, malotilate, baclofen, probucol, sulfamonomethoxine, levodopa,

timiperone, cetraxate hydrochloride, flopropione, budralazine, oxypertine, and epirizol. Pharmaceutically active ingredients and nutritional ingredients may be incorporated into a solid composition singly or in combination of two or more species.

Generally-employed various composition additives may further be incorporated into a solid composition comprising the disintegrant of the present invention, so long as such additives do not impede the effect of the disintegrant (e.g., shortening of disintegration time, enhancement of stability with passage of time). Examples of composition additives include excipients, disintegrants, binders, lubricants, coloring agents, sweeteners, and sweetening agents. Specific examples of these additives will next be described.

Examples of excipients include water-soluble excipients such as lactose, sucrose, fructose, glucose, mannitol, sorbitol, macrogol, powder hydrogenated maltose starch syrup, and hydrogenated lactose, and water-insoluble excipients such as corn starch, potato starch, wheat starch, rice starch, crystalline cellulose, light anhydrous silicic acid, dried aluminum hydroxide gel, magnesium aluminosilicate, calcium silicate, synthetic aluminum silicate, synthetic hydrotalcite, hydrate silicon dioxide, magnesium oxide, magnesium hydroxide, calcium carbonate, and calcium hydrogenphosphate.

Examples of disintegrants include starches such as partially pregelatinized starch, hydroxypropyl starch, and sodium carboxymethyl starch; celluloses such as crystalline

cellulose, powder cellulose, low substituted hydroxypropylcellulose, carmellose, carmellose calcium, croscarmellose sodium, and carboxymethylethylcellulose; polymer compounds such as alginic acid, guar gum, casein formamide, pectin, ion exchange resin, cross-linking polyvinylpyrrolidone; and inorganic substances such as bentonite (colloidal hydrated aluminum silicate) and beegum (a mixture of magnesium silicate and aluminum silicate).

Examples of binders include methylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinyl alcohol, and polyvinylpyrrolidone.

Examples of lubricants include magnesium stearate, calcium stearate, talc, and sucrose esters of fatty acids.

Examples of coloring agents include food yellow No. 5, food dye red No. 2, food dye blue No. 2, food lake dye, yellow ferric oxide, and titanium oxide.

Examples of sweeteners include Aspartame, Stevia, sormatin, sodium saccharin, and dipotassium glycyrrhetinate.

Examples of sweetening agents include L-menthol, camphor, peppermint, sodium L-glutamate, disodium inosinate, and magnesium chloride.

These composition additives may be appropriately incorporated into a solid composition during a suitable process in the course of production of the solid composition.

A solid composition comprising the disintegrant of the present invention may be produced through a known process for producing a solid composition. Examples of granulation

methods which may be employed include a fluidized-bed granulation, an agitating granulation, an agitating fluidized-bed granulation, an extrusion granulation, a spray granulation, and a pulverization granulation.

An example process for producing a solid composition by means of a fluidized-bed granulation method will next be described.

Erythritol and, if desired, excipients such as lactose and corn starch are incorporated into pharmaceutically active ingredients and/or nutritional ingredients, and the resultant mixture is granulated by use of an aqueous solution of a binder such as hydroxypropylcellulose or polyvinyl alcohol through a fluidized-bed granulation-drying machine. If desired, a sweetener such as Aspartame is added to the granules, and mixed by means of a mixing machine to produce granules, powders, or fine granules. Incidentally, a lubricant such as magnesium stearate or talc may be added to the thus-granulated product in a required amount, and after mixing, the resultant mixture may be tableted by means of a tableting machine, producing tablets or chewable tablets.

Examples

The present invention will next be described in more detail by way of examples, which should not be construed as limiting the invention thereto.

<Test method>

The following tests were performed in order to describe

the present invention in more detail.

(1) Measurement of water solubility

A saturated aqueous solution of a sample was prepared at 37°C, and the resultant solution was filtered by use of a membrane filter. A predetermined volume of the filtrate was precisely weighed and dried by means of a freeze-drying method, so that the water content was obtained. Water solubility was calculated on the basis of the thus-obtained water content.

(2) Measurement of viscosity of a saturated aqueous solution

A saturated aqueous solution of a sample was prepared at 37°C, and the resultant solution was filtered by use of a membrane filter. The viscosity of the solution was measured by use of the resultant filtrate at 37°C by means of a B-type viscometer.

(3) Hardness of a tablet

The hardness of a tablet in a radial direction was measured by use of a tablet hardness tester (Schleuniger tablet hardness tester, product of Freund Industrial Co., Ltd.). Measurement was performed on five sample tablets, and the mean value is shown in Tables below.

(4) Disintegration test

According to the disintegration test method of tablets in Pharmacopoeia of Japan (13th edition), measurement was performed on six sample tablets by use of a disintegration tester (product of Toyama Sangyo) without use of a disk. The mean value is shown in Tables below.

[illegible]

(6) Tableting pressure

(7) Increase in weight by moisture absorption

(8) Percentage of increase in volume

Test Example 1

13

carmellose sodium were measured in the same manner as in Test Example 2. These compounds had been dried in a drier at 80°C for one hour, and then employed as samples.

Table 2

	Sample	25°C, 75% open air, 7 days
Test Example 2	Erythritol	0.03%
	Trehalose	0.99%
	Xylitol	0.05%
	Maltose	0.06%
Reference Example 2	Corn starch	8.53%
	Low substituted hydroxypropylcellulose	14.09%
	Carmellose	11.55%
	Carmellose calcium	17.49%
	Carmellose Sodium	21.07%

As is apparent from Table 2, erythritol, trehalose, xylitol, and maltose absorb little moisture, whereas water-swellaable disintegrants in Reference Example 2; i.e., low substituted hydroxypropylcellulose, carmellose, carmellose calcium, and carmellose sodium, absorb moisture, and the increase in weight by moisture absorption ranges from 10 to 20%.

Example 1

Lactose and corn starch were added into a fluidized-bed granulation-drying machine on the basis of the formulations of Examples 1-1 through 1-3 shown in Table 2, and mixed for three minutes. The resultant mixture was granulated by use of a 5 w/v% aqueous solution (100 ml) of hydroxypropylcellulose (HPC_L, product of Nippon Soda Co.,

Ltd.) under the following conditions: spray pressure 1.5 kg/cm², spray solution rate 15 ml/minute. After being dried, the resultant granules were sieved by use of a 16-mesh sieve (1000 μm). Erythritol [product of Nikken Chemicals Co., Ltd., sieved through 42 mesh (350 μm)] and magnesium stearate were added to the thus-sieved granules on the basis of the formulations of Examples 1-1 through 1-3 shown in Table 3, and mixed. Subsequently, the mixture was prepared into tablets by use of a punch having a flat impact face (diameter: 10 mm) in a single tableting machine at three different tableting pressures (from low to high pressure). The weight of a tablet was 400 mg. In Comparative Example 1, on the basis of the formulation shown in Table 3, tablets were produced in the same manner as in Example 1. The thus-produced tablets were subjected to the disintegration test. The results are shown in Table 4 and Fig. 1.

Table 3

Formulation	Example			Comparative Example
	1-1	1-2	1-3	1
Lactose	247	219	191	275
Corn starch	106	94	82	118
Erythritol	40	80	120	-
Hydroxypropylcellulose	5	5	5	5
Magnesium stearate	2	2	2	2
Total	400	400	400	400

Note) In the formulation, unit is gram (g).

Table 4

	Tableting pressure	Weight (g)	Hardness (kg)	Disintegration time (minute)
Example 1-1	530	402	2.0	3.2
	1075	400	4.9	2.8
	1450	400	8.0	3.3
Example 1-2	520	400	1.3	1.8
	1100	403	4.2	1.5
	1515	404	6.6	2.0
Example 1-3	505	402	1.0	1.2
	1000	401	2.9	1.3
	1600	399	5.0	1.3
Comparative Example 1	525	402	2.6	3.3
	1050	404	6.8	3.4
	1475	400	10.4	3.4

As is apparent from Table 4 and Fig. 1, the disintegration time of tablets of Examples 1-1 through 1-3 is shortened as compared with that of Comparative Example 1. In addition, when the amount of erythritol incorporated into the tablet is increased, the disintegration time of a tablet becomes shorter.

Example 2

Ethenzamide and corn starch were added into a fluidized-bed granulation-drying machine on the basis of the

formulation of Example 2 shown in Table 5, and mixed for three minutes. The resultant mixture was granulated by use of a 5 w/v% aqueous solution (200 ml) of hydroxypropylcellulose under the following conditions: spray pressure 1.5 kg/cm², spray solution rate 15 ml/minute. After being dried, the resultant granules were sieved by use of a 16-mesh sieve. Erythritol and magnesium stearate were added to the thus-sieved granules on the basis of the formulation of Example 2 shown in Table 5, and mixed. Subsequently, the mixture was prepared into tablets by use of a punch having a flat impact face (diameter: 10 mm) in a single tableting machine at three different tableting pressures (from low to high pressure). The weight of a tablet was 400 mg. In Comparative Examples 2-1 and 2-2, on the basis of the formulations shown in Table 5, tablets were produced in the same manner as in Example 2. The thus-produced tablets were subjected to the disintegration test. The results are shown in Table 6 and Fig. 2.

Table 5

Formulation	Example 2	Comp. Ex. 2-1	Comp. Ex. 2-2
Ethenzamide	250	250	250
Corn starch	56	136	56
Erythritol	80	-	-
Low substituted hydroxypropylcellulose	-	-	80
Hydroxypropylcellulose	10	10	10
Magnesium stearate	4	4	4
Total	400	400	400

Note) In the formulation, unit is gram (g).

Table 6

	Tableting pressure	Weight (g)	Hardness (kg)	Disintegration time (minute)
Example 2	525	404	4.1	1.7
	1040	405	8.1	2.5
	1550	406	11.8	3.3
Comparative Example 2-1	515	401	3.5	14.6
	1035	400	8.2	18.7
	1550	403	12.3	13.7
Comparative Example 2-2	540	409	3.0	2.4
	1065	404	7.9	4.2
	1530	404	11.2	7.0

As is apparent from Table 6 and Fig. 2, the disintegration time of tablets of Example 2 is shortened as compared with that of Comparative Example 2-1. In addition, the disintegration time of tablets of Example 2 is equal to or shorter than that required for tablets of Comparative Example 2-2 in which a water-swellaable disintegrant, low substituted hydroxypropylcellulose, is incorporated.

Example 3

Tranexamic acid and corn starch were added into a fluidized-bed granulation-drying machine on the basis of the formulation of Example 3 shown in Table 7, and were mixed for three minutes. The resultant mixture was granulated by use of a 5 w/v% aqueous solution (100 ml) of polyvinyl alcohol (partially hydrolyzed, PVA_{205s}, product of Kuraray Co., Ltd.) under the following conditions: spray pressure 1.5 kg/cm², spray solution rate 15 ml/minute. After being dried, the resultant granules were sieved by use of a 16-mesh sieve. Erythritol and magnesium stearate were added to the thus-

sieved granules on the basis of the formulation of Example 3 shown in Table 7, and mixed. Subsequently, the mixture was prepared into tablets by use of a punch having a flat impact face (diameter: 10 mm) in a single tableting machine at three different tableting pressures (from low to high pressure). The weight of a tablet was 400 mg. In Comparative Examples 3-1 and 3-2, on the basis of the formulations shown in Table 7, tablets were produced in the same manner as in Example 3. The thus-produced tablets were subjected to the disintegration test. The results are shown in Table 8 and Fig. 3.

Table 7

Formulation	Example 3	Comp. Ex. 3-1	Comp. Ex. 3-2
Tranexamic acid	250	250	250
Corn starch	63	143	63
Erythritol	80	-	-
Low substituted hydroxypropylcellulose	-	-	80
Hydroxypropylcellulose	5	5	5
Magnesium stearate	2	2	2
Total	400	400	400

Note) In the formulation, unit is gram (g).

Table 8

	Tableting pressure (kg/punching g)	Weight (g)	Hardness (kg)	Disintegration time (minute)
Example 3	530	403	1.3	1.3
	1015	407	2.6	0.9
	1530	413	3.7	1.5
Comparative Example 3-1	500	401	1.3	2.6
	1015	403	3.0	3.1
	1515	408	4.5	3.7
Comparative Example 3-2	510	401	2.6	0.9
	1030	402	5.7	1.9
	1535	406	8.0	3.4

As is apparent from Table 8 and Fig. 3, the disintegration time of tablets of Example 3 is shortened as compared with that of Comparative Example 3-1. In addition, the disintegration time of tablets of Example 3 is equal to that required for tablets of Comparative Example 3-2 in which a water-swellable disintegrant, low substituted hydroxypropylcellulose, is incorporated.

Example 4

Erythritol and corn starch were added into a fluidized-bed granulation-drying machine on the basis of the formulation of Example 4 shown in Table 9, and were mixed for three minutes. The resultant mixture was granulated by use of water (800 ml) under the following conditions: spray pressure 2.0 kg/cm², spray solution rate 20 ml/minute. After being dried, the resultant granules were sieved by use of a 16-mesh sieve. Magnesium stearate (0.5 wt.%) was added to the thus-sieved granules and mixed. Subsequently, the

mixture was prepared into tablets by use of a punch having a flat impact face (diameter: 10 mm) in a single tableting machine at a tableting pressure of 300-1300 kg/punching. The weight of a tablet was 400 mg. The thus-obtained tablets were subjected to the disintegration test and the disintegration test in the oral cavity. The results are shown in Table 10.

Example 5

Example 6

Example 7

formulation of Example 7 shown in Table 9, to thereby obtain tablets. The thus-obtained tablets were subjected to the disintegration test and the disintegration test in the oral cavity. The results are shown in Table 10.

Comparative Example 4

The procedure of Example 4 was repeated, except that erythritol was replaced by D-sorbitol (product of Towa Chemical Industry Co., Ltd.) on the basis of the formulation of Comparative Example 4 shown in Table 9, to thereby obtain tablets. The thus-obtained tablets were subjected to the disintegration test and the disintegration test in the oral cavity. The results are shown in Table 10.

Comparative Example 5

The procedure of Example 4 was repeated, except that erythritol was replaced by hydrogenated maltose starch syrup (product of Towa Chemical Industry Co., Ltd.) on the basis of the formulation of Comparative Example 5 shown in Table 9, to thereby obtain tablets. The thus-obtained tablets were subjected to the disintegration test and the disintegration test in the oral cavity. The results are shown in Table 10.

Table 9

Formulation	Ex. 4	Ex. 5	Ex. 6	Ex. 7	Comp. Ex. 4	Comp. Ex. 5
Corn starch	240	240	240	240	240	240
Erythritol	560	-	-	-	-	-
Trehalose	-	560	-	-	-	-
Xylitol	-	-	560	-	-	-
Maltose	-	-	-	560	-	-
D-Sorbitol	-	-	-	-	560	-
Hydrogenated maltose starch syrup	-	-	-	-	-	560
Total	800	800	800	800	800	800

Note) In the formulation, unit is gram (g).

Table 10

	Tableting pressure (kg/punching)	Weight (g)	Hardness (kg)	Disinte- gration time (second)	Disinte- gration time in the oral cavity (second)
Ex. 4	1091	400	4.0	16	15-22
Ex. 5	450	412	2.8	53	50-60
Ex. 6	850	400	1.8	43	51-78
Ex. 7	730	398	0.6	40	21-26
Comp. Ex. 4	1100	406	2.0	46	70-145
Comp. Ex. 4	960	412	2.3	108	72-159

As is apparent from Table 10, the disintegration time of tablets of Example 4 through 7 is relatively shorter than that required for tablets of Comparative Examples 4 and 5. Particularly, the disintegration time of tablets of Example 4 through 7 in the oral cavity is considerably shortened. Thus, erythritol, trehalose, xylitol, and maltose may be an excellent disintegrant to be employed in a solid composition which is rapidly disintegrated in the oral cavity.

Example 8

Ethenzamide, corn starch, and erythritol were added into a fluidized-bed granulation-drying machine on the basis of the formulation of Example 8 shown in Table 11, and were mixed for three minutes. The resultant mixture was granulated by use of a 5 w/v% aqueous solution (200 ml) of hydroxypropylcellulose under the following conditions: spray pressure 1.5 kg/cm², spray solution rate 15 ml/minute. After being dried, the resultant granules were sieved by use of a 16-mesh sieve. Magnesium stearate were added to the thus-sieved granules on the basis of the formulation of Example 8 shown in Table 11, and mixed. Subsequently, the mixture was prepared into tablets by use of a punch having a flat impact face (diameter: 10 mm) in a single tableting machine at a tableting pressure of 100-800 kg/punching. The weight of a tablet was 400 mg. The thus-obtained tablets were subjected to the disintegration test and stability tests under moisture absorption conditions. The results are shown in Tables 12 and 13.

Example 9

The procedure of Example 8 was repeated, except that erythritol was replaced by trehalose on the basis of the formulation of Example 9 shown in Table 11, to thereby obtain tablets. The thus-obtained tablets were subjected to the disintegration test and stability tests under moisture absorption conditions. The results are shown in Tables 12 and 13.

Comparative Example 6

The procedure of Example 8 was repeated, except that erythritol was replaced by croscarmellose sodium on the basis of the formulation of Comparative Example 6 shown in Table 11, to thereby obtain tablets. The thus-obtained tablets were subjected to the disintegration test and stability tests under moisture absorption conditions. The results are shown in Tables 12 and 13.

Table 11

Formulation	Example 8	Example 9	Comparative Example 6
Ethenzamide	250	250	250
Corn starch	56	56	116
Erythritol	80	-	-
Trehalose	-	80	-
Croscarmellose sodium	-	-	20
Hydroxypropylcellulose	10	10	10
Magnesium stearate	4	4	4
Total	400	400	400

Note) In the formulation, unit is gram (g).

Table 12

		Tableting pressure (kg/punching)	Weight (g)	Hardness (kg)	Disintegrating time (second)
Example 8	(1)	390	405	7.7	2.0
	(2)	680	401	11.8	2.5
Example 9	(1)	150	409	3.9	7.8
	(2)	300	408	7.0	11.7
Comp. Ex. 6	(1)	290	407	3.5	11.9
	(2)	600	409	7.3	11.1

Table 13

		Initial	25°C, 75% open air, 7 days	40°C, 75% open air, 7 days
Example 8-(2)	Hardness (kg)	11.8	11.0	9.6
	Disintegration time (minute)	2.5	2.5	2.5
	Increase in weight by moisture absorption (%)	-	1.3	0.4
	Tablet size (mm)	10.06	10.12	10.12
	Tablet thickness (mm)	4.56	4.65	4.70
	Percentage of increase in volume (%)	-	3.3	3.7
Example 9-(2)	Hardness (kg)	7.0	6.2	4.8
	Disintegration time (minute)	11.7	8.3	10.2
	Increase in weight by moisture absorption (%)	-	1.2	0.4
	Tablet size (mm)	10.06	10.02	10.10
	Tablet thickness (mm)	4.97	5.03	5.04
	Percentage of increase in volume (%)	-	0.4	2.1
Comparative Example 6-(2)	Hardness (kg)	7.3	4.3	3.2
	Disintegration time (minute)	11.1	10.7	10.9
	Increase in weight by moisture absorption (%)	-	3.0	1.5
	Tablet size (mm)	10.09	10.28	10.25
	Tablet thickness (mm)	4.82	5.06	5.04
	Percentage of increase in volume (%)	-	9.0	7.9

As is apparent from Table 12, the disintegration time

of tablets of Examples 8 and 9 is equal to or shorter than that required for tablets of Comparative Example 6 in which a water-swellable disintegrant, croscarmellose sodium, is incorporated. As is apparent from Table 13, tablets of Examples 8 and 9 exhibit excellent stability as compared with those of Comparative Example 6. Namely, in the tablets of Examples 8 and 9, reduction in hardness, increase in weight by moisture absorption, and percentage of increase in volume are small as compared with those of Comparative Example 6. In the tablets of Examples 8 and 9, slight increase in volume is attributed not to erythritol and trehalose which are not hygroscopic, but to corn starch incorporated into the tablets, which absorbs moisture.

Industrial Applicability

The disintegration time of a solid composition comprising the disintegrant of the present invention is equal to or shorter than that comprising a conventionally-used water-swellable disintegrant. The disintegrant of the present invention exhibits no swellability, and thus increase in volume of the agent is not observed with passage of time. Particularly, when the agent is incorporated into a film-coated or sugar-coated tablet, stability of the tablet over time is enhanced. When the disintegrant of the present invention is incorporated into powders, granules, chewable tablets, or shaped products which rapidly disintegrate or dissolve in the oral cavity, such a solid composition

containing the agent can provide a favorable sensation on oral administration, since the composition does not provide a gritty sensation in the oral cavity and the composition dissolves rapidly in the oral cavity. A solid composition comprising the disintegrant of the present invention does not require a complicated production process comprising a number of steps. Namely, the composition can be produced through a general production process, resulting in low cost and high productivity.

Claims

1. A disintegrant comprising a substance which is solid at room temperature and has a water solubility of 30 wt.% or more at 37°C, a saturated aqueous solution of the substance having a viscosity of 50 mPa·s or less at 37°C.

2. A disintegrant containing one or more substances selected from the group consisting of erythritol, trehalose, xylitol, and maltose.

3. A solid composition containing a disintegrant as described in claim 1 or 2.

4. A solid composition containing a disintegrant comprising a substance which is solid at room temperature and has a water solubility of 30 wt.% or more at 37°C, a saturated aqueous solution of the substance having a viscosity of 50 mPa·s or less at 37°C, wherein the amount of the disintegrant is 5-99 wt.% with respect to the total weight of the solid composition.

5. A solid composition containing a disintegrant containing one or more substances selected from the group consisting of erythritol, trehalose, xylitol, and maltose, wherein the amount of the disintegrant is 5-99 wt.% with respect to the total weight of the solid composition.

ABSTRACT

The present invention relates to a disintegrant comprising a substance which is solid at room temperature and has a water solubility of 30 wt.% or more, a saturated aqueous solution of the substance having a viscosity of 50 mPa·s.

Fig. 1





Fig. 2


Relation between disintegration time and hardness
in Example 2



DOCT 20 64573560

Fig. 3

Relation between disintegration time and hardness
in Example 3.



Declaration and Power of Attorney For Patent Application

特許出願宣言書及び委任状

Japanese Language Declaration

日本語宣言書

下記の氏名の発明者として、私は以下の通り宣言します。

私の住所、私書箱、国籍は下記の私の氏名の後に記載された通りです。

下記の名称の発明に関して請求範囲に記載され、特許出願している発明内容について、私が最初かつ唯一の発明者（下記の氏名が一つの場合）もしくは最初かつ共同発明者（下記の名称が複数の場合）であると信じています。

「崩壊剤」

上記発明の明細書は、

☐ 本書に添付されています。

☒ 1999年1月13日に提出され、米国出願番号または特許協定条約国際出願番号を PCT/JP99/00083 とし、
(該当する場合) _____ に訂正されました。

私は、特許請求範囲を含む上記訂正後の明細書を検討し、内容を理解していることをここに表明します。

私は、連邦規則法典第37編第1条56項に定義されるとおり、特許資格の有無について重要な情報を開示する義務があることを認めます。

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled.

DISINTEGRANT

the specification of which

☐ is attached hereto.

☒ was filed on January 13, 1999

as United States Application Number or

PCT International Application Number

PCT/JP99/00083 and was amended on

_____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

Japanese Language Declaration
(日本語宣言書)

私は、米国法典第35編119条 (a) - (d) 項又は365条 (b) 項に基づき下記の、米国以外の国の少なくとも一カ国を指定している特許協力条約365 (a) 項に基づく国際出願、又は外国での特許出願もしくは発明者証の出願についての外国優先権をここに主張するとともに、優先権を主張している、本出願の前に出願された特許または発明者証の外国出願を以下に、枠内をマークすることで、示しています。

Prior Foreign Application(s)
外国での先行出願

10-5610

Japan

(Number)
(番号)

(Country)
(国名)

(Number)
(番号)

(Country)
(国名)

私は、第35編米国法典119条 (e) 項に基づいて下記の米国特許出願規定に記載された権利をここに主張いたします。

(Application No.)
(出願番号)

(Filing Date)
(出願日)

私は、下記の米国法典第35編120条に基づいて下記の米国特許出願に記載された権利、又は米国を指定している特許協力条約365条 (c) に基づく権利をここに主張します。また、本出願の各請求範囲の内容が米国法典第35編112条第1項又は特許協力条約で規定された方法で先行する米国特許出願に開示されていない限り、その先行米国出願書提出日以降で本出願書の日本国内または特許協力条約国際提出日までの期間中に入手された、連邦規則法典第37編1条56項で定義された特許資格の有無に関する重要な情報について開示義務があることを認識しています。

(Application No.)
(出願番号)

(Filing Date)
(出願日)

(Application No.)
(出願番号)

(Filing Date)
(出願日)

私は、私自信の知識に基づいて本宣言書中で私が行なう表明が真実であり、かつ私の入手した情報と私の信じるところに基づく表明が全て真実であると信じていること、さらに故意になされた虚偽の表明及びそれと同等の行為は米国法典第18編第1001条に基づき、罰金または拘禁、もしくはその両方により処罰されること、そしてそのような故意による虚偽の声明を行なえば、出願した、又は既に許可された特許の有効性が失われることを認識し、よってここに上記のごとく宣誓を致します。

I hereby claim foreign priority under Title 35, United States Code, Section 119 (a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed.

Priority Claimed
優先権主張

14/01/1998

(Day/Month/Year Filed)
(出願年月日)

☒

Yes
はい

☐

No
いいえ

(Day/Month/Year Filed)
(出願年月日)

☐

Yes
はい

☐

No
いいえ

I hereby claim the benefit under Title 35, United States Code, Section 119(e) of any United States provisional application(s) listed below.

(Application No.)
(出願番号)

(Filing Date)
(出願日)

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s), or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code Section 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of application.

(Status: Patented, Pending, Abandoned)
(現況: 特許許可済、係属中、放棄済)

(Status: Patented, Pending, Abandoned)
(現況: 特許許可済、係属中、放棄済)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Japanese Language Declaration
(日本語宣言書)

委任状：私は下記の発明者として、本出願に関する一切の手続きを米特許商標局に対して遂行する弁理士または代理人として、下記の者を指名いたします。
(弁護士、または代理人の指名及び登録番号を明記のこと)

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith: (list name and registration number)

Norman F. Oblon, Reg. No. 24,618; Marvin J. Spivak, Reg. No. 24,913; C. Irvin McClelland, Reg. No. 21,124; Gregory J. Maier, Reg. No. 25,599; Arthur I. Neustadt, Reg. No. 24,854; Richard D. Kelly, Reg. No. 27,757; James D. Hamilton, Reg. No. 28,421; Eckhard H. Kuesters, Reg. No. 28,870; Robert T. Pous, Reg. No. 29,099; Charles L. Gholz, Reg. No. 26,395; Vincent J. Sunderdick, Reg. No. 29,004; William E. Beaumont, Reg. No. 30,996; Robert F. Gnuse, Reg. No. 27,295; Jean-Paul Lavalleye, Reg. No. 31,451; Stephen G. Baxter, Reg. No. 32,884; Martin M. Zoltick, Reg. No. 35,745; Robert W. Hahl, Reg. No. 33,893; Richard L. Treanor, Reg. No. 36,379; Steven P. Wehrouch, Reg. No. 32,829; John T. Goolkasian, Reg. No. 26,142; Richard L. Chinn, Reg. No. 34,305; Steven E. Lipman, Reg. No. 30,011; Carl E. Schlier, Reg. No. 34,426; James J. Kulbaski, Reg. No. 34,648; Richard A. Neifeld, Reg. No. 35,299; J. Derek Mason, Reg. No. 35,270; Surinder Sachar, Reg. No. 34,423; Christina M. Gadiano, Reg. No. 37,628; Jeffrey B. McIntyre, Reg. No. 36,867; and Paul E. Rauch, Reg. No. 38,591 with full powers of substitution and revocation.

30

書類送付先

Send Correspondence to:

OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT, P.C.
FOURTH FLOOR
1755 JEFFERSON DAVIS HIGHWAY
ARLINGTON, VIRGINIA 22202 U.S.A.

直接電話連絡先：(名前及び電話番号)


Direct Telephone Calls to: (name and telephone number)
(703) 413-3000

単独発明者または第一の共同発明者の氏名 村上 敏男	Full name of sole or first joint inventor Toshio MURAKAMI	1-00
発明者の署名 Toshio Murakami	Inventor's signature	Date June 4, 2000
住所 134-8630 日本国東京都江戸川区北葛西 1-16-13 第一製薬株式会社東京研究開発センター内	Residence c/o Daiichi Pharmaceutical Co., Ltd. Tokyo R&D Center, 16-13, Kitakasai 1-chome, Edogawa-ku, TOKYO 134-8630 JAPAN	
国籍 日本国	Citizenship Japanese	JPX
郵便の宛先 住所に同じ	Post Office Address same as above	
第二の共同発明者の氏名 井 紀孝	Full name of second joint inventor, if any Noritaka II	2-00
第二の共同発明者の署名 Noritaka II	Second joint Inventor's signature	Date June 4, 2000
住所 134-8630 日本国東京都江戸川区北葛西 1-16-13 第一製薬株式会社東京研究開発センター内	Residence c/o Daiichi Pharmaceutical Co., Ltd. Tokyo R&D Center, 16-13, Kitakasai 1-chome, Edogawa-ku, TOKYO 134-8630 JAPAN	
国籍 日本国	Citizenship Japanese	JPX
郵便の宛先 住所に同じ	Post Office Address same as above	

(第三以降の共同発明者についても同様に記載し、署名すること)

(Supply similar information and signature for third and subsequent joint inventors.)

Japanese Language Declaration
(日本語宣誓書)

第三の共同発明者の氏名 櫻井 裕之	Full name of third joint inventor, if any Hiroyuki SAKURAI 3-00
第三の共同発明者の署名  日付 2000 6/4	Third joint inventor's signature Date June 4, 2000
住所 134-8630 日本国東京都江戸川区北葛西1-16-13 第一製薬株式会社東京研究開発センター内	Residence c/o Daiichi Pharmaceutical Co., Ltd. Tokyo R&D Center, 16-13, Kitakasai 1-chome, Edogawa-ku, TOKYO 134-8630 JAPAN JPX
国籍 日本国	Citizenship Japanese
郵便の宛先 住所に同じ	Post Office Address same as above

第四の共同発明者の氏名	Full name of fourth joint inventor, if any
第四の共同発明者の署名 日付	Fourth joint inventor's signature Date
住所	Residence
国籍	Citizenship
郵便の宛先	Post Office Address

第五の共同発明者の氏名	Full name of fifth joint inventor, if any
第五の共同発明者の署名 日付	Fifth joint inventor's signature Date
住所	Residence
国籍	Citizenship
郵便の宛先	Post Office Address

第六の共同発明者の氏名	Full name of sixth joint inventor, if any
第六の共同発明者の署名 日付	Sixth joint inventor's signature Date
住所	Residence
国籍	Citizenship
郵便の宛先	Post Office Address